Here's a glimpse of Pfizer's plan for them.
According to a media statement by Pfizer, the company will be closing its Singapore Pfizer Clinical Research Unit (PCRU) in 2013.
The decision was made as part of Pfizer Worldwide Research & Development’s ongoing comprehensive effort to increase operational efficiencies and to create a more focused and sustainable R&D engine.
They assured that this will not impact any of Pfizer’s other operations in Singapore, or Pfizer’s other R&D operations in Asia. Both Singapore and Asia as a region, remain core to Pfizer’s global business strategy
Approximately 30 Pfizer colleagues work at the Singapore PCRU. All colleagues may apply for open positions in WRD or other Pfizer organizations within Singapore and globally based on interests and qualifications. Moreover, we will ensure that we help colleagues impacted by this decision through this transition.
"We are confident that these changes will enhance our competitiveness and allow us to target investments that derive the greatest value based on current and future research strategies," the statement read.
More From Singapore Business Review